#1
#1 out of 1
business1d ago
TEDCO's Major Q4 2025 Investments in Life Sciences & MedTech
- TEDCO ended 2025 with a strong Q4 showing in life sciences and medtech investing, combining direct funding with SBIR/STTR matching.
- Major Q4 investments include VerImmune, NasaClip, LASARRUS, and Natáur, spanning immunotherapy, non-invasive devices, remote monitoring, and bio-based taurine.
- The quarter also expanded SBIR/STTR matching, with $875,000 awarded across 13 Maryland companies.
- VerImmune secured the largest life science investment of the quarter, $500,000 to advance its ViP technology.
- NasaClip developed a hands-free, painless device for nosebleed treatment, aiming for clinical and at-home use.
- LASARRUS focuses on remote patient monitoring for COPD with wearable tech.
- Natáur secured $250,000 to advance bio-based taurine production, supporting sustainable biomanufacturing.
- The report notes a broader market backdrop, including thawing capital markets and renewed pharma deal-making.
- TEDCO positions Maryland startups to be ready for 2026 private capital as momentum returns.
Vote 0